Cita APA

V, G., B, G., A, A., S, R., B, H., M, K., . . . A, P. (2025). Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults.

Citación estilo Chicago

V, Galán-Gómez, et al. Siltuximab for the Treatment of Early Complications After Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults. 2025.

Cita MLA

V, Galán-Gómez, et al. Siltuximab for the Treatment of Early Complications After Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults. 2025.